Key Highlights
- 35% lower total care costs for CGM patients using medical benefits over pharmacy.
- 23% higher adherence to CGM therapy through medical benefit.
- CCS presented findings at ADCES and ISPOR conferences.
- AI-powered PropheSee™ model boosts patient adherence by up to 50%.
Source: Business Wire
Notable Quotes
- “CGMs are only effective if people use them. This first-of-its-kind research demonstrates that a physician’s decision to direct a patient to use their medical benefit instead of their pharmacy benefit when accessing a medical device can seriously impact health outcomes and costs of care.” — Dr. Arti Masturzo, Chief Medical Officer at CCS
- “They’ve coached me on how to use a CGM and helped educate me on the value of using my medical benefit.” — Scott Gerberich, Patient
SoHC's Take
The research from CCS underscores the importance of ensuring that patients access continuous glucose monitoring (CGM) devices through their medical benefits instead of pharmacy benefits. The data-driven insights highlight significant cost savings and improved adherence, which are crucial for both patient outcomes and healthcare sustainability. CCS’s integration of education, coaching, and AI-driven predictive tools further cements its role as a leader in chronic care management, particularly for diabetes care. With rising CGM adoption and an urgent need for effective patient support, CCS’s innovations, like PropheSee™, offer a promising model for the future of proactive chronic care management.
Heading
Related

#28 – Dr. Arti Masturzo, Chief Medical Officer at CCS
Episode Details: Welcome back to Bringing Virtual Care Home! In this episode host Tina Null is joined by Dr. Arti Masturzo, Chief Medical Officer at CCS to discuss how CCS provides advance diabetes technology in the home and the importance of engagement and trust inside this healthcare division. In this…

Vyne Medical® Acquires Extract Systems® to Enhance Healthcare Automation
Key Highlights Vyne Medical® acquires Extract Systems®, a leader in data extraction solutions.Accelerates healthcare automation by integrating AI and machine learning capabilities.Reduces data transcription time from 5 minutes to 30 seconds, achieving 90%+ accuracy.Enhances clinical workflow and revenue cycle management for hospitals and health systems.Expands into government services to improve automation accuracy and support.Source: Business…

Nura Bio Secures $140M in Series A Financing and Appoints Shilpa Sambashivan, Ph.D., as CEO
Key Highlights Nura Bio closes $140M Series A financing to support clinical development.Shilpa Sambashivan, Ph.D., appointed as CEO following Phase 1 success of NB-4746.NB-4746 is a brain-penetrant SARM1 inhibitor with potential neuroprotective benefits.Phase 1 trial results show NB-4746 was well-tolerated and achieved target plasma exposure.Source: Business Wire Notable Quotes “Under Shilpa’s leadership, Nura Bio has…